Sudemycin e influences alternative splicing and changes chromatin modifications

Paolo Convertini, Manli Shen, Philip M. Potter, Gustavo Palacios, Chandraiah Lagisetti, Pierre De La Grange, Craig Horbinski, Yvonne N. Fondufe-Mittendorf, Thomas R. Webb, Stefan Stamm

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


Sudemycin E is an analog of the pre-messenger RNA splicing modulator FR901464 and its derivative spliceostatin A. Sudemycin E causes the death of cancer cells through an unknown mechanism. We found that similar to spliceostatin A, sudemycin E binds to the U2 small nuclear ribonucleoprotein (snRNP) component SF3B1. Native chromatin immunoprecipitations showed that U2 snRNPs physically interact with nucleosomes. Sudemycin E induces a dissociation of the U2 snRNPs and decreases their interaction with nucleosomes. To determine the effect on gene expression, we performed genome-wide array analysis. Sudemycin E first causes a rapid change in alternative pre-messenger RNA splicing, which is later followed by changes in overall gene expression and arrest in the G2 phase of the cell cycle. The changes in alternative exon usage correlate with a loss of the H3K36me3 modification in chromatin encoding these exons. We propose that sudemycin E interferes with the ability of U2 snRNP to maintain an H3K36me3 modification in actively transcribed genes. Thus, in addition to the reversible changes in alternative splicing, sudemycin E causes changes in chromatin modifications that result in chromatin condensation, which is a likely contributing factor to cancer cell death.

Original languageEnglish
Pages (from-to)4947-4961
Number of pages15
JournalNucleic Acids Research
Issue number8
StatePublished - Apr 2014
Externally publishedYes


Dive into the research topics of 'Sudemycin e influences alternative splicing and changes chromatin modifications'. Together they form a unique fingerprint.

Cite this